SBP-7455

• Description :

  SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; ULK

• Type :

  Reference compound

• Related Pathways :

  Autophagy

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/sbp-7455.html

• Concentration :

  10mM

• Purity :

  98.01

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  FC(C1=CN=C(NC2=CC=C(OC)C(OC)=C2)N=C1NC3CC3)(F)F

• Molecular Formula :

  C16H17F3N4O2

• Molecular Weight :

  354.33

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Huiyu Ren, et al. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2020 Dec 10;63 (23) :14609-14625

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  ULK1; ULK2

• CAS Number :

  [1884222-74-5]